Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $115.00.

In the most recent trading session, Gilead Sciences (GILD) closed at $93.85, indicating a -1.57% shift from the previous trading day.

The stock's fall snapped a two-day winning streak.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

This was the stock's second consecutive day of gains.

Gilead Sciences GILD +2.54% Get Free Report has outperformed the market over the past 20 years by 4.74% on an annualized ...

Janney Montgomery Scott LLC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 47.0% ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $93.07 which represents a slight increase of $0.15 or 0.16% from the prior close of $92.92. The stock opened at $92.36 and ...

We recently compiled a list of the 8 Best Humane Stocks to Invest in Now. In this article, we are going to take a look at ...

Gilead Sciences Inc (GILD) stock saw a decline, ending the day at $92.92 which represents a decrease of $-0.12 or -0.13% from the prior close of $93.04. The stock opened at $93.03 and touched a low of ...